Barclays PLC Nautilus Biotechnology, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Barclays PLC holds 106,174 shares of NAUT stock, worth $259,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,174

Previous 106,174 -0.0%

Holding current value

$259,064

Previous $303,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.24 - $3.08 $105,412 - $144,941	47,059 Added 79.61%	106,174 $303,000
Q2 2024 Aug 14, 2024	SELL	$2.22 - $3.0 $39,913 - $53,937	-17,979 Reduced 23.32%	59,115 $139,000
Q1 2024 May 15, 2024	SELL	$2.41 - $3.18 $81,564 - $107,623	-33,844 Reduced 30.51%	77,094 $227,000
Q4 2023 Feb 15, 2024	BUY	$2.34 - $3.39 $141,317 - $204,728	60,392 Added 119.48%	110,938 $332,000
Q3 2023 Nov 07, 2023	SELL	$2.87 - $3.94 $2,984 - $4,097	-1,040 Reduced 2.02%	50,546 $160,000
Q2 2023 Aug 03, 2023	SELL	$2.21 - $4.52 $31,947 - $65,341	-14,456 Reduced 21.89%	51,586 $200,000
Q1 2023 May 04, 2023	BUY	$1.67 - $2.77 $19,584 - $32,483	11,727 Added 21.59%	66,042 $182,000
Q4 2022 Feb 13, 2023	BUY	$1.55 - $2.47 $16,705 - $26,621	10,778 Added 24.76%	54,315 $98,000
Q3 2022 Nov 03, 2022	SELL	$1.96 - $3.13 $727 - $1,161	-371 Reduced 0.84%	43,537 $92,000
Q2 2022 Aug 12, 2022	BUY	$2.64 - $4.84 $6,314 - $11,577	2,392 Added 5.76%	43,908 $118,000
Q1 2022 May 16, 2022	BUY	$3.5 - $5.3 $145,306 - $220,034	41,516 New	41,516 $180,000

Others Institutions Holding NAUT

# of Institutions

Shares Held

64.3M

Call Options Held

1.9K

Put Options Held

100

View Full List

About Nautilus Biotechnology, Inc.

Ticker NAUT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,663,000
Market Cap $304M
Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...

More about NAUT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account